Pulling SEC filings + quote and writing the call…

SUPERNUS PHARMACEUTICALS, INC.
Next earnings Aug 3, 2026 · consensus $0.44 EPS, $209M rev
Last earnings +1.2% on 2026-05-05
Revenue grew 8.6% YoY; but unprofitable (net margin -5.4%).
SUPERNUS PHARMACEUTICALS, INC. shows $719M in FY2025 revenue (+8.6% YoY), a -5.4% net margin, and -3.6% ROE.
Sources: SEC EDGAR (CIK 0001356576, latest 10-Q filed 2026-05-05) · EODHD · as of 6/26/2026, 11:32:32 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $580M | $667M | $608M | $662M | $719M |
| Gross profit | — | — | — | — | — |
| Operating income | $86.0M | $46.1M | -$5.27M | $81.7M | -$62.3M |
| Net income | $53.4M | $60.7M | $1.32M | $73.9M | -$38.5M |
| Diluted EPS | $0.98 | $1.04 | $0.02 | $1.32 | -$0.68 |
| Net margin | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1047 tracked peers · median
2 buys · 1 member · last 180d
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-03-18 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Exercise | 7.25K @ $39.40 | $286K |
| 2026-03-18 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sell | 6.84K @ $49.55 | $339K |
| 2026-03-18 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sell | 412.00 @ $50.48 | $20.8K |
| 2026-03-17 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Exercise | 22.8K @ $39.40 | $896K |
| 2026-03-17 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Exercise | 12.3K @ $36.75 | $450K |
| 2026-03-17 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Exercise | 15.0K @ $38.60 | $579K |
| 2026-03-17 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sell | 27.7K @ $49.95 | $1.38M |
| 2026-03-17 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Sell | 22.3K @ $50.73 | $1.13M |
| 2026-03-16 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Exercise | 22.8K @ $36.75 | $836K |
| 2026-03-16 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Exercise | 4.25K @ $29.61 | $126K |
| 2026-03-16 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Exercise | 18.0K @ $32.20 | $580K |
| 2026-03-16 | Bhatt Padmanabh P. Sr. VP of IP, CSO | Exercise | 5.00K @ $27.94 | $140K |